Overexpression of histone deacetylase 2 predicts unfavorable prognosis in human gallbladder carcinoma

Pathology and Oncology Research

Volumn 19, Issue 3, 2013, Pages 397-403

  Du, Xilin ^a   Zhao, Huadong ^a   Zang, Li ^a   Song, Nuan ^a   Yang, Tao ^a   Dong, Rui ^a   Yin, Jikai ^a   Wang, Chengguo ^a   Lu, Jianguo ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathology; Disease free survival; Histone deacetylase 2; Overall survival; Primary gallbladder carcinoma

Indexed keywords

HISTONE DEACETYLASE 2; HDAC2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; ANALYSIS OF VARIANCE; ANTIBODY SPECIFICITY; BIOSYNTHESIS; ENZYMOLOGY; GALLBLADDER TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; FEMALE; GALLBLADDER NEOPLASMS; HISTONE DEACETYLASE 2; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ORGAN SPECIFICITY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84880333449     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-012-9592-y     Document Type: Article

References (29)

1. Misra S, Chaturvedi A, Misra NC, Sharma ID (2003) Carcinoma of the gallbladder. Lancet Oncol 4:167-176
2. Chen Y, Chen Y, Yu G, Ding H (2011) Lymphangiogenic and angiogentic microvessel density in gallbladder carcinoma. Hepatogastroenterology 58:20-25
3. Araida T, Higuchi R, Hamano M, Kodera Y, Takeshita N, Ota T, Yoshikawa T, Yamamoto M, Takasaki K (2009) Should the extrahepatic bile duct be resected or preserved in R0 radical surgery for advanced gallbladder carcinoma? results of a Japanese Society of Biliary Surgery Survey: a multicenter study. Surg Today 39:770-779
4. Kokudo N, Makuuchi M, Natori T, Sakamoto Y, Yamamoto J, Seki M, Noie T, Sugawara Y, Imamura H, Asahara S, Ikari T (2003) Strategies for surgical treatment of gallbladder carcinoma based on information available before resection. Arch Surg 138:741-750
5. Davies GF, Ross AR, Arnason TG, Juurlink BH, Harkness TA (2010) Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Lett 288:236-250
6. Brandl A, Heinzel T, Kramer OH (2009) Histone deacetylases: salesmen and customers in the post-translational modification market. Biol Cell Auspices Eur Cell Biol Organ 101:193-205
7. Ishdorj G, Graham BA, Hu X, Chen J, Johnston JB, Fang X, Gibson SB (2008) Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. J Biol Chem 283:16818-16829
8. Mehdi O, Françoise S, Sofia CL, Urs G, Kevin Z, Bernard S, Igor S, Anabela CD, Dominique L, Eric M, Ali O (2012) HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA). Pancreatology 12:146-155
9. Spiegel S, Milstien S, Grant S (2012) Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 31:537-551
10. Lee JH, Jeong EG, Choi MC, Kim SH, Park JH, Song SH, Park J, Bang YJ, Kim TY (2010) Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. Mol Cells 30:107-112
11. Xu LN, Wang X, Zou SQ (2008) Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. World J Gastroenterol 14:2578-2581
12. Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y, Ikeda H, Nimura Y, Nagino M, Nakanuma Y (2010) Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 101:355-362
13. Kitamura T, Connolly K, Ruffino L, Ajiki T, Lueckgen A, Digiovanni J, Kiguchi K. (2012) The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol. In press
14. Willis-Martinez D, Richards HW, Timchenko NA, Medrano EE (2010) Role of HDAC1 in senescence, aging, and cancer. Exp Gerontol 45:279-285
15. Schüler S, Fritsche P, Diersch S, Arlt A, Schmid RM, Saur D, Schneider G (2010) HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol Cancer 9:80
16. Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, Lee JY, Nam SW (2012) HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem 113:2167-2177
17. Patani N, Jiang WG, Newbold RF, Mokbel K (2011) Histone-modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. Anticancer Res 31:4115-4125
18. Quint K, Agaimy A, Di Fazio P, Montalbano R, Steindorf C, Jung R, Hellerbrand C, Hartmann A, Sitter H, Neureiter D, Ocker M (2011) Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch 459:129-139
19. Aghdassi A, Sendler M, Guenther A, Mayerle J, Behn CO, Heidecke CD, Friess H, Büchler M, Evert M, Lerch MM, Weiss FU (2012) Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut 61:439-448
20. Ramsey MR, He L, Forster N, Ory B, Ellisen LW (2011) Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer Res 71:4373-4379
21. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737-749
22. Khier H, Bartl S, Schuettengruber B, Seiser C (1999) Molecular cloning and characterization of the mouse histone deacetylase 1 gene: integration of a retrovirus in 129SV mice. Biochim Biophys Acta 1489:365-373
23. Brunmeir R, Lagger S, Seiser C (2009) Histone deacetylase HDAC1/HDAC2-controlled embryonic development and cell differentiation. Int J Dev Biol 53:275-289
24. Yamaguchi T, Cubizolles F, Zhang Y, Reichert N, Kohler H, Seiser C, Matthias P (2010) Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes Dev 24:455-469
25. Jurkin J, Zupkovitz G, Lagger S, Grausenburger R, Hagelkruys A, Kenner L, Seiser C (2011) Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis. Cell Cycle 10:406-412
26. Huang BH, Laban M, Leung CH, Lee L, Lee CK, Salto-Tellez M, Raju GC, Hooi SC (2005) Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 12:395-404
27. Harms KL, Chen X (2007) Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity. Cancer Res 67:3145-3152
28. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Göttlicher M (2004) Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5:455-463
29. Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY (2009) Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 45:610-614